A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 26.1% year on year to $186.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.32 per share was 32.5% above analysts’ consensus estimates.
A number of stocks traded in opposite directions in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
iRhythm Technologies (IRTC) aligns with Mark Minervini's trend-following strategy, showing strong technicals, rising revenue, and earnings growth. A top performer in healthcare, IRTC is near its 52-week high with bullish momentum.
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC)
jumped 18% in the morning session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast.
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 26.1% year on year to $186.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.32 per share was 32.5% above analysts’ consensus estimates.
iRhythm Technologies (IRTC) reported Q2 2025 revenue of $186.69M, beating estimates, with a narrower loss of -$0.32 EPS. Stock remained steady post-earnings.
Medical technology company iRhythm Technologies (NASDAQ:IRTC)
will be announcing earnings results this Thursday after market hours. Here’s what to look for.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC)
jumped 3.2% in the afternoon session after the positive sentiment from Wall Street analysts who saw further potential in the company. The digital healthcare firm has garnered a "Moderate Buy" consensus rating from analysts. Based on ten recent analyst ratings, the average twelve-month price target for iRhythm sits at $138.60, suggesting potential upside from its current trading level. Nine out of ten of these analysts rate the stock as a "Buy." This bullish stance from market experts likely reflects confidence in iRhythm's Zio service, a platform that uses wearable biosensors and cloud-based data analytics to diagnose cardiac arrhythmias. The company's focus on integrating artificial intelligence to provide clinically actionable insights for physicians positions it well within the growing digital health sector.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at iRhythm (NASDAQ:IRTC) and its peers.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
